Impact of treatment duration and dosing on efficacy and safety in a phase 3 study of panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma
Impact of treatment duration and dosing on efficacy and safety in a phase 3 study of panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma
Languages of Item:
English
Abstract:
Empty abstract
Publication year:
2015
Authors:
San-Miguel, JF Hungria, VTM Yoon, S-S Beksac, M Dimopoulos, MA Elghandour, A Jedrzejczak, WW Guenther, A Nakorn, TN Siritanaratkul, N others
